3α-chloro-5αH-androstane | 54155-81-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3α-chloro-5αH-androstane
• 英文别名: 3α-Chloro-5α-androstane；3α-Chlor-5α-androstan；(3R,5S,8S,9S,10S,13S,14S)-3-chloro-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene
• CAS: 54155-81-6
• 化学式: C₁₉H₃₁Cl
• 分子量: 294.908
• InChiKey: GBGACQPAYVDHJA-PHFHYRSDSA-N

物化性质

• 沸点：
  373.8±11.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  表雄酮 在 氢氧化钾 、 磺酰氯 、 一水合肼 作用下， 以 吡啶 、 二乙二醇 为溶剂， 反应 1.0h， 生成 3α-chloro-5αH-androstane
  参考文献：
  名称：

  Proton NMR analyses, shielding mechanisms, coupling constants, and conformations in steroids bearing halogen, hydroxy, and oxo groups and double bonds

  摘要：

  DOI：

  10.1021/ja00310a046

文献信息

• SHIP INHIBITION TO COMBAT OBESITY
  申请人：KERR William G.

  公开号：US20160129017A1

  公开（公告）日：2016-05-12

  The present invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.

  本发明涉及使用SHIP1抑制剂和pan-SHIP1/2抑制剂在各种方法中的应用，包括但不限于：（i）治疗肥胖或减少肥胖患者的体脂肪的方法；（ii）限制骨发育在患有骨质疏松或硬化病的患者中的方法；（iii）治疗或预防糖尿病的方法；（iv）减少葡萄糖不耐受或胰岛素抵抗的方法；以及（v）降低胆固醇的方法。
• Cowell; Davis; Mathieson, Journal of the Chemical Society. Perkin transactions I, 1974, vol. 0, # 13, p. 1505 - 1513
  作者：Cowell、Davis、Mathieson、Nicklin

  DOI：——

  日期：——
• SHIP INHIBITORS AND USES THEREOF
  申请人：The Research Foundation For The State University Of New York

  公开号：US20170051006A1

  公开（公告）日：2017-02-23

  The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) a method of inhibiting a SHIP1 protein in a cell; (iii) a method of selectively inhibiting a SHIP1 protein in a cell; (iv) a method for treating or preventing graft-versus-host disease (GVHD) in a recipient of an organ or tissue transplant; (v) a method of modulating SHIP activity in a cell expressing SHIP1 or SHIP2; (vi) a method of ex vivo or in vitro treatment of transplants; (vii) a method of inhibiting tumor growth and metastasis in a subject; (viii) a method of treating a hematologic malignancy in a subject; (ix) a method of inducing apoptosis of multiple myeloma cells; (x) a method of treating multiple myeloma in a subject; (xi) a method of inhibiting the proliferation of a human breast cancer cell; and (xii) a method of treating breast cancer in a subject.
• SHIP INHIBITION TO INDUCE EXPRESSION OF GRANULOCYTE COLONY STIMULATING FACTOR IN A SUBJECT
  申请人：THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

  公开号：US20170128461A1

  公开（公告）日：2017-05-11

  The present invention relates to the use SHIP inhibitors to induce expression of granulocyte colony stimulating factor (G-CSF) in a subject, thereby promoting expansion of hematopoietic and mesenchymal stem cells.
• Proton NMR analyses, shielding mechanisms, coupling constants, and conformations in steroids bearing halogen, hydroxy, and oxo groups and double bonds
  作者：H. J. Schneider、U. Buchheit、N. Becker、G. Schmidt、U. Siehl

  DOI：10.1021/ja00310a046

  日期：1985.11